SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--()--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CytomX Therapeutics, Inc. (“CytomX” or “the Company”) (NASDAQ: CTMX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between May 17, 2018 and May 13, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before July 20, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. CytomX minimized problems with its drug candidate CX-072’s efficacy as documented in its PROCLAIM-CX-072 clinical program. The Company also downplayed CX-2009’s efficacy and safety problems as observed in the PROCLAIM-CX-2009 clinical program. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about CytomX, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

Release Summary

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc.

#Hashtags

$Cashtags

Contacts

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com